Safilens is proud to announce the publication in the international scientific journal Ophthalmology and Therapy of an important peer-reviewed article titled “Post-market Surveillance Analysis of Refractive Data in Users of Delivery Tyro, a Tyrosine-Releasing Contact Lens.”
The article presents the results of an analysis conducted on 241 young myopic individuals (average age: 14.7 years) who used Delivery Tyro daily disposable contact lenses for a 12-month period. The study was carried out in collaboration with the Advanced Contact Lens Research Center at the University of Salento and the Veneto Eye Bank Foundation.
The results are extremely encouraging: after one year of use, the average myopic progression was just −0.04 diopters (D), compared to an expected value of −0.28 D according to a meta-analysis of reference data. 94% of the eyes examined showed no significant change in refraction (≤ −0.25 D), with an 85% reduction in myopia progression compared to expected values. These data were collected as part of a post-market surveillance program involving 55 optometrists across Italy.
Understanding the Clinical Significance
Delivery Tyro represents an innovative approach to myopia control. It is the first daily contact lens with controlled release of tyrosine, a precursor of dopamine—a key neurotransmitter involved in regulating eye growth. The lenses also incorporate hyaluronic acid and TSP, enhancing comfort and tear film stability.
“The study results provide initial clinical confirmation of the potential of Delivery Tyro as a practical and effective option for myopia control, offering users the highest possible visual acuity without compromise or risk,” says Daniele Bazzocchi, co-author of the article and General Manager of Safilens.
The Delivery contact lens line is now recognized for its integrated approach combining optics and biotechnology, with the goal of innovating the contact lens sector through biofunctional solutions—advanced medical devices for visual wellness.
The full study is available open access at: